Dehaze

Name: Dehaze
Brand: Dehaze

AI Native

Detecting and personally intervening chronic diseases before symptoms occur.

Est 2023|Valuation $330K

LinkedIn 1K|Web traffic 2K|FTEs 9|HQ Fürstenfeldbruck, Germany

- The term "copilot" is used by multiple vendors and can have different meanings in healthcare; for some vendors it denotes ambient documentation, while Dehaze emphasizes longitudinal risk profiling across multimodal data. - Potential strengths for Dehaze: if the platform supports comprehensive multimodal data ingestion (notes, imaging, genomics) and provides explainable risk flags grounded in guidelines, it could complement documentation tools. - Potential strengths for competitors: larger incumbent vendors and well-funded ambient-scribe vendors often provide more mature IT integrations, documented compliance artifacts, uptime guarantees, and a larger base of referenceable customers. - Adoption signals: Dehaze appears early-stage based on accelerator participation and seed financing; early-stage status typically implies faster product iteration but higher procurement risk. Sources: Local startup press coverage; company profile entries in business databases; official vendor announcements and profiles.

01Competitive Landscape

Narrative analysis

The term "copilot" is used by multiple vendors and can have different meanings in healthcare; for some vendors it denotes ambient documentation, while Dehaze emphasizes longitudinal risk profiling across multimodal data.
Potential strengths for Dehaze: if the platform supports comprehensive multimodal data ingestion (notes, imaging, genomics) and provides explainable risk flags grounded in guidelines, it could complement documentation tools.
Potential strengths for competitors: larger incumbent vendors and well-funded ambient-scribe vendors often provide more mature IT integrations, documented compliance artifacts, uptime guarantees, and a larger base of referenceable customers.
Adoption signals: Dehaze appears early-stage based on accelerator participation and seed financing; early-stage status typically implies faster product iteration but higher procurement risk.

Sources: Local startup press coverage; company profile entries in business databases; official vendor announcements and profiles.

	Dehaze (vendor site)	Nuance DAX Copilot	Abridge
Starting Price	Not publicly listed	Not publicly listed	Not publicly listed
Primary Use Case	Longitudinal risk detection and multimodal data unification (patient/payer/provider contexts)	Automating clinical documentation via ambient capture and enterprise workflows	Clinical conversation intelligence and documentation generation at enterprise scale
Key Strength	Focus on longitudinal risk identification and harmonization of multiple medical data formats	Established enterprise footprint for documentation and ambient capture	Market adoption for clinical conversation intelligence and documentation
Key Weakness	Limited independent reviews; limited public security/compliance documentation; unclear integration list	Primarily focused on documentation rather than longitudinal risk profiling	Pricing opacity; documentation-centric focus rather than chronic risk detection

Dehaze

01Competitive Landscape

Narrative analysis

02Market Map

01Competitive Landscape

Narrative analysis

02Market Map